Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Active Pharma Ingredients

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1199196

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1199196

High Potency APIs (HPAPIs)

PUBLISHED:
PAGES: 192 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 14850

Add to Cart

Description

Table of Contents

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global High Potency APIs (HPAPIs) Market to Reach $42.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for High Potency APIs (HPAPIs) estimated at US$21.6 Billion in the year 2022, is projected to reach a revised size of US$42.1 Billion by 2030, growing at aCAGR of 8.7% over the period 2022-2030. Innovative, one of the segments analyzed in the report, is projected to record 8.4% CAGR and reach US$28.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Generic segment is readjusted to a revised 9.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $6.3 Billion, While China is Forecast to Grow at 8.2% CAGR

The High Potency APIs (HPAPIs) market in the U.S. is estimated at US$6.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.3 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 7.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR.

Select Competitors (Total 38 Featured):

  • AbbVie, Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Mylan Pharmaceuticals, Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Show more
Product Code: MCP12373

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • High Potency APIs (HPAPIs) - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for High Potency APIs (HPAPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for High Potency APIs (HPAPIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Captive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Captive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Captive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Merchant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Merchant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Merchant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Hormonal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Glaucoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 28: World High Potency APIs (HPAPIs) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: USA 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: USA 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: USA 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • JAPAN
    • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • CHINA
    • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: China Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: China 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: China Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: China 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: China Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: China 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • EUROPE
    • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for High Potency APIs (HPAPIs) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • FRANCE
    • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: France Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: France 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: France Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: France 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: France Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: France 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • GERMANY
    • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: UK 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: UK 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: UK 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Rest of World 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!